Arcus Biosciences, Inc.
3928 Point Eden Way, Hayward, CA 94545
1800 Sierra Point Parkway, Brisbane, CA 94005
United States
228 articles about Arcus Biosciences, Inc.
-
Arcus Biosciences Announces New Employment Inducement Grants - April 09, 2024
4/9/2024
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 45,000 shares of the Company’s common stock at an exercise price per share of $16.97, which was the closing price on April 8, 2024, and restricted stock units to acquire a total of 22,500 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - March 26, 2024
3/26/2024
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 18,400 shares of the Company’s common stock at an exercise price per share of $16.47, which was the closing price on March 25, 2024, and restricted stock units to acquire a total of 9,200 shares of the Company’s common stock.
-
Arcus Biosciences Announces New Employment Inducement Grants - March 11, 2024
3/11/2024
Arcus Biosciences, Inc., announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 13,800 shares of the Company’s common stock at an exercise price per share of $17.99, which was the closing price on March 8, 2024, and restricted stock units to acquire a total of 6,900 shares of the Company’s common stock.
-
Arcus Biosciences to Participate in Two Upcoming March 2024 Investor Conferences
2/28/2024
Arcus Biosciences, a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in March.
-
Arcus Biosciences Announces New Employment Inducement Grants - February 27, 2024
2/27/2024
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 17,600 shares of the Company’s common stock at an exercise price per share of $19.53, which was the closing price on February 26, 2024, and restricted stock units to acquire a total of 8,800 shares of the Company’s common stock.
-
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
2/21/2024
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023.
-
Arcus Biosciences Announces New Employment Inducement Grants - February 09, 2024
2/9/2024
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 71,900 shares of the Company’s common stock at an exercise price per share of $15.20, which was the closing price on February 8, 2024, and restricted stock units to acquire a total of 35,950 shares of the Company’s common stock.
-
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
2/7/2024
Arcus Biosciences (NYSE:RCUS) announced that its management team will host a conference call and webcast on Wednesday, February 21, 2024 at 2:00 PM PT / 5:00 PM ET to discuss pipeline updates and details of the Company’s financial results for the quarter and year ended December 31st, 2023.
-
Gilead Sciences and Arcus Biosciences have amended their collaboration agreement in an effort to accelerate an anti-TIGIT program, the companies announced Monday.
-
Gilead and Arcus Announce Amended Collaboration and Equity Investment
1/29/2024
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 26, 2024
1/26/2024
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 76,700 shares of the Company’s common stock at an exercise price per share of $15.26, which was the closing price on January 25, 2024, and restricted stock units to acquire a total of 38,350 shares of the Company’s common stock.
-
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
1/16/2024
Arcus Biosciences, Inc. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences.
-
Arcus Biosciences Announces New Employment Inducement Grants - December 11, 2023
12/11/2023
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 19,600 shares of the Company’s common stock at an exercise price per share of $15.77, which was the closing price on December 8, 2023, and restricted stock units to acquire a total of 9,800 shares of the Company’s common stock.
-
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
12/4/2023
Exelixis, Inc. and Arcus Biosciences announced that the companies have entered into a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation tyrosine kinase inhibitor, in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma.
-
Arcus Biosciences Announces New Employment Inducement Grants - November 27, 2023
11/27/2023
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common stock at an exercise price per share of $14.06, which was the closing price on November 24, 2023, and restricted stock units to acquire a total of 6,300 shares of the Company’s common stock.
-
Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
11/14/2023
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference in Miami, FL.
-
Arcus Biosciences Announces New Employment Inducement Grants - November 13, 2023
11/13/2023
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 31,200 shares of the Company’s common stock at an exercise price per share of $16.01, which was the closing price on November 8, 2023, and restricted stock units to acquire a total of 15,600 shares of the Company’s common stock.
-
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update
11/7/2023
Arcus Biosciences, Inc. (NYSE:RCUS) today reported financial results for the third quarter ended September 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers.
-
A combination of Gilead Sciences’ domvanalimab and Arcus Biosciences’ zimberelimab, along with chemo, has shown an “encouraging” overall response rate in a mid-stage study.
-
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
11/6/2023
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate and six-month progression-free survival rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study.